Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.
Analyst Ratings
This is a breakdown of current ratings and target prices for Neurocrine Biosciences and Amneal Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurocrine Biosciences | 0 | 4 | 19 | 1 | 2.88 |
| Amneal Pharmaceuticals | 0 | 2 | 8 | 0 | 2.80 |
Neurocrine Biosciences currently has a consensus price target of $202.32, indicating a potential upside of 16.00%. Amneal Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 5.94%. Given Neurocrine Biosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Amneal Pharmaceuticals.
Valuation & Earnings
This table compares Neurocrine Biosciences and Amneal Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neurocrine Biosciences | $2.86 billion | 6.17 | $478.60 million | $6.74 | 25.88 |
| Amneal Pharmaceuticals | $3.02 billion | 2.30 | $72.06 million | $0.42 | 51.69 |
Neurocrine Biosciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Neurocrine Biosciences and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurocrine Biosciences | 18.98% | 23.39% | 16.22% |
| Amneal Pharmaceuticals | 4.17% | 283.50% | 7.79% |
Risk and Volatility
Neurocrine Biosciences has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Summary
Neurocrine Biosciences beats Amneal Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
